DianeLinnehan, Author at Phelan-McDermid Syndrome Foundation

Neuren’s Phase 3 NNZ-2591 Trial for Phelan-McDermid Syndrome is Now Active!

Neuren’s Phase 3 NNZ-2591 Trial for Phelan-McDermid Syndrome is Now Active! by: Lauren Schmitt, PhDDate: December 15, 2025The Phelan-McDermid Syndrome Foundation is…

PMSF NAMES ROBBIE BAKER AS CHIEF EXECUTIVE OFFICER

Phelan-McDermid Syndrome Foundation Names Robbie Baker as Chief Executive Officer by: Denise Croden, President, Phelan-McDermid Syndrome FoundationWe are excited to share…

Because no family should walk this path alone

Giving Tuesday is December 2nd and we have some exciting news!

We surpassed our Giving Tuesday match and raised $77K (exact total to be posted later). We ope you feel the appreciation…

Jaguar Gene Therapy to Start a Clinical Trial in Phelan-McDermid syndrome

We have breaking news! Jaguar Gene Therapy has received approval from the FDA to conduct a gene therapy clinical trial in Phelan-McDermid syndrome. This is a major milestone for our community and for drug development in Phelan-McDermid syndrome! This will be the first trial aiming to target genetic underpinnings of Phelan-McDermid syndrome.